<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Clinical trials on FinanClub</title>
    <link>https://finan.club/tags/clinical-trials/</link>
    <description>Recent content in Clinical trials on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Mon, 11 Mar 2024 09:03:54 +0000</lastBuildDate><atom:link href="https://finan.club/tags/clinical-trials/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>TGTX</title>
      <link>https://finan.club/us/tgtx/</link>
      <pubDate>Mon, 11 Mar 2024 09:03:54 +0000</pubDate>
      
      <guid>https://finan.club/us/tgtx/</guid>
      <description>score:113
Chances: TG Therapeutics, Inc. has announced the presentation of data from the ULTIMATE I &amp;amp; II Phase 3 trials evaluating BRIUMVI® in patients with relapsing forms of multiple sclerosis, indicating potential positive outcomes from the trials. The company has reported strong financial results, with BRIUMVI U.</description>
    </item>
    
    <item>
      <title>SANA</title>
      <link>https://finan.club/us/sana/</link>
      <pubDate>Sat, 02 Mar 2024 09:02:41 +0000</pubDate>
      
      <guid>https://finan.club/us/sana/</guid>
      <description>score:46
Chances: Sana Biotechnology has successfully cleared IND for B-cell mediated autoimmune diseases with initial clinical data expected in 2024 Early data from ongoing ARDENT trial suggests the ability to dose safely, demonstrate the desired immune evasion profile, and early clinical efficacy Risks: Markets are awaiting the latest inflation numbers and the debate regarding soft vs hard landing is expected to persist on Wall Street High institutional ownership implies Sana Biotechnology&amp;rsquo;s stock price is sensitive to their decisions Score:46 chances characters count - risks characters count = 46</description>
    </item>
    
    <item>
      <title>IBRX</title>
      <link>https://finan.club/us/ibrx/</link>
      <pubDate>Tue, 27 Feb 2024 09:04:54 +0000</pubDate>
      
      <guid>https://finan.club/us/ibrx/</guid>
      <description>score:142
Chances: Completion of enrollment for safety portions of a clinical trial is a positive indicator of progress for the company Findings from Patient-Reported Outcomes (PROs) and positive interim results from the QUILT 3.032 study showcase the potential of ImmunityBio’s therapies Acceptance for review of the Biologics License Application (BLA) for N-803 by the FDA demonstrates a significant milestone for the company Risks: The success of the clinical trials and the FDA review are crucial for the company’s future prospects, and any setbacks in these processes could impact the stock performance Competitive landscape and regulatory environment for immunotherapy companies may pose challenges Score:142 chances characters count - risks characters count = 142</description>
    </item>
    
    <item>
      <title>ARWR</title>
      <link>https://finan.club/us/arwr/</link>
      <pubDate>Thu, 04 Jan 2024 09:10:03 +0000</pubDate>
      
      <guid>https://finan.club/us/arwr/</guid>
      <description>score:114
Chances: The company has successfully priced an underwritten registered offering, indicating strong investor interest and potential for significant capital influx. The filing of an application for clearance to initiate a Phase 1/2a clinical trial of ARO-CFB demonstrates progress in the company’s pipeline development.</description>
    </item>
    
  </channel>
</rss>
